Orthocell Ltd (ASX:OCC)’s Paul Anderson joins Proactive’s Elisha Newell for an overview of Orthocell’s position in the regenerative medicine market and its focus on the musculoskeletal space. Anderson also highlights the recently executed global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc – one of the largest dental implant companies in the world – for OCC’s Striate+™ dental membrane used for dental-guided bone and tissue regeneration procedures. Anderson explains the nature of the deal, why it is such a big milestone, the national benefit and how it has strengthened the company’s cash position and the plans moving forward including the scale up of product manufacturing.
Orthocell signs defining licence and distribution agreement
